Physiopathology Study of the Microbiota Biodiversity of HIV Seropositive Patients

ANRS, Emerging Infectious Diseases80 enrolled

Overview

The bacterial diversity of HIV patients digestive microbiota seropositive is poorly understood, it remains to be defined.

Study Type

OBSERVATIONAL

Enrollment

Conditions

HIV-1 Infection

Interventions

Physiopathology studyOTHER

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patient aged 18 or more. * Patients with a confirmed diagnosis of HIV infection 1. * Patient who signed an informed consent form. * Patient affiliated or beneficiary of a social security system. Exclusion Criteria: * Patient known to be suffering from inflammatory bowel disease (Crohn's disease or ulcerative colitis). * Patient HIV-2 or HIV-1/HIV-2 co-infected * Patient having received immunotherapy * Patient participating in another research. * Pregnant women, parturient or lactating person under guardianship, or deprived of liberty by a judicial or administrative decision.

Locations (4)

Centre Henri Mondor

Créteil, France

Service de Médecine Interne et Immunologie Clinique

Le Kremlin-Bicêtre, France

IHU Méditerranée Infection; Hôpital Nord, AP-HM

Marseille, France

Service de maladies Infectieuses

Marseille, France

Outcomes

Primary Outcomes

Proportion and type of OTU (Operational Taxonomic Unit) assigned to the rank of phylum genus and species of bacteria in the intestinal microbiota of HIV-1 seropositive patients.

Time frame: Baseline

Secondary Outcomes

Proportion and OTU types in the gastrointestinal microbiota of HIV-1 seropositive patients compared to the general population

Time frame: Baseline

Proportion and OTU types in the gastrointestinal microbiota of HIV-1 seropositive patients based on CD4, viral load, the Elite controller status, antiretroviral and antibiotic treatment and the existence of invasive bacterial infections.

Time frame: Baseline

Proportion and OTU types in the gastrointestinal microbiota of HIV-1 seropositive patients based on inflammation parameters (IL-6, TNF-a, IP-10), CRPus, CD14 and integrity of the epithelial barrier (I-FABP).

Time frame: Baseline

Transcriptomic analysis in the groups that present differences in the microbiota and analysis of lymphocyte populations Th17 and Treg.

Time frame: Baseline

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.